Silence Therapeutics
Silence Therapeutics[edit | edit source]
Silence Therapeutics is a biotechnology company focused on developing therapies that harness the body's natural mechanisms to silence disease-causing genes. The company specializes in RNA interference (RNAi) technology, which is a biological process where RNA molecules inhibit gene expression or translation, effectively silencing targeted genes.
History[edit | edit source]
Silence Therapeutics was founded with the aim of advancing RNAi technology to create innovative treatments for a variety of diseases. Over the years, the company has developed a robust pipeline of therapeutic candidates targeting a range of conditions, including rare genetic disorders and cardiovascular diseases.
Technology[edit | edit source]
The core technology of Silence Therapeutics is based on RNAi, a process that utilizes small interfering RNA (siRNA) molecules to target and degrade specific messenger RNA (mRNA) molecules, preventing the production of disease-causing proteins. This approach allows for precise targeting of genes involved in disease processes.
RNA Interference[edit | edit source]
RNA interference is a natural cellular mechanism that regulates gene expression. It involves the use of double-stranded RNA molecules to trigger the degradation of complementary mRNA, thereby reducing the expression of specific genes. Silence Therapeutics leverages this mechanism to develop therapies that can silence genes associated with various diseases.
Pipeline[edit | edit source]
Silence Therapeutics has a diverse pipeline of RNAi-based therapeutics. Some of the key areas of focus include:
- Rare Genetic Disorders: Developing treatments for conditions caused by specific genetic mutations.
- Cardiovascular Diseases: Targeting genes involved in the regulation of cholesterol and other factors contributing to heart disease.
- Other Therapeutic Areas: Exploring RNAi applications in oncology and other fields.
Collaborations[edit | edit source]
Silence Therapeutics has established partnerships with several pharmaceutical companies to advance its RNAi technology and expand its therapeutic offerings. These collaborations aim to accelerate the development and commercialization of RNAi-based treatments.
Related pages[edit | edit source]
This article is a Biotechnology stub. You can help WikiMD by expanding it!
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
